Literature DB >> 29487132

The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation.

Thomas F Pack1,2, Margo I Orlen2, Caroline Ray2, Sean M Peterson2, Marc G Caron3,4,5.   

Abstract

The dopamine D2 receptor (D2R) is a G protein-coupled receptor (GPCR) that is critical for many central nervous system functions. The D2R carries out these functions by signaling through two transducers: G proteins and β-arrestins (βarrs). Selectively engaging either the G protein or βarr pathway may be a way to improve drugs targeting GPCRs. The current model of GPCR signal transduction posits a chain of events where G protein activation ultimately leads to βarr recruitment. GPCR kinases (GRKs), which are regulated by G proteins and whose kinase action facilitates βarr recruitment, bridge these pathways. Therefore, βarr recruitment appears to be intimately tied to G protein activation via GRKs. Here we sought to understand how GRK2 action at the D2R would be disrupted when G protein activation is eliminated and the effect of this on βarr recruitment. We used two recently developed biased D2R mutants that can preferentially interact either with G proteins or βarrs as well as a βarr-biased D2R ligand, UNC9994. With these functionally selective tools, we investigated the mechanism whereby the βarr-preferring D2R achieves βarr pathway activation in the complete absence of G protein activation. We describe how direct, G protein-independent recruitment of GRK2 drives interactions at the βarr-preferring D2R and also contributes to βarr recruitment at the WT D2R. Additionally, we found an additive interaction between the βarr-preferring D2R mutant and UNC9994. These results reveal that the D2R can directly recruit GRK2 without G protein activation and that this mechanism may have relevance to achieving βarr-biased signaling.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G protein–coupled receptor (GPCR); GPCR kinases; bioluminescence resonance energy transfer (BRET); dopamine receptor; drug action; pharmacology

Mesh:

Substances:

Year:  2018        PMID: 29487132      PMCID: PMC5912473          DOI: 10.1074/jbc.RA117.001300

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors.

Authors:  J A Pitcher; J Inglese; J B Higgins; J L Arriza; P J Casey; C Kim; J L Benovic; M M Kwatra; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

2.  G protein-coupled receptor kinases: Past, present and future.

Authors:  Konstantin E Komolov; Jeffrey L Benovic
Journal:  Cell Signal       Date:  2017-07-12       Impact factor: 4.315

3.  Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

Authors:  Bernard Masri; Ali Salahpour; Michael Didriksen; Valentina Ghisi; Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

Review 4.  The physiological relevance of functional selectivity in dopamine signalling.

Authors:  N M Urs; M G Caron
Journal:  Int J Obes Suppl       Date:  2014-07-08

5.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

6.  A beta-adrenergic receptor kinase dominant negative mutant attenuates desensitization of the beta 2-adrenergic receptor.

Authors:  G Kong; R Penn; J L Benovic
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

7.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.

Authors:  L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

8.  Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells.

Authors:  H Kurose; T Katada; T Amano; M Ui
Journal:  J Biol Chem       Date:  1983-04-25       Impact factor: 5.157

Review 9.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

10.  Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling.

Authors:  Elisa Alvarez-Curto; Asuka Inoue; Laura Jenkins; Sheikh Zahir Raihan; Rudi Prihandoko; Andrew B Tobin; Graeme Milligan
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

View more
  19 in total

1.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.

Authors:  Lauren M Slosky; Yushi Bai; Krisztian Toth; Caroline Ray; Lauren K Rochelle; Alexandra Badea; Rahul Chandrasekhar; Vladimir M Pogorelov; Dennis M Abraham; Namratha Atluri; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick Maloney; Hong Yuan; Zibo Li; William C Wetsel; Anthony B Pinkerton; Lawrence S Barak; Marc G Caron
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

2.  Carboxy-Terminal Phosphoregulation of the Long Splice Isoform of Free-Fatty Acid Receptor-4 Mediates β-Arrestin Recruitment and Signaling to ERK1/2.

Authors:  Ilya S Senatorov; Ameneh Cheshmehkani; Rebecca N Burns; Kirti Singh; Nader H Moniri
Journal:  Mol Pharmacol       Date:  2020-03-04       Impact factor: 4.436

3.  Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations.

Authors:  Laura M Wingler; Matthias Elgeti; Daniel Hilger; Naomi R Latorraca; Michael T Lerch; Dean P Staus; Ron O Dror; Brian K Kobilka; Wayne L Hubbell; Robert J Lefkowitz
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

4.  Spatial regulation of GPR64/ADGRG2 signaling by β-arrestins and GPCR kinases.

Authors:  Pedram Azimzadeh; Sarah C Talamantez-Lyburn; Katarina T Chang; Asuka Inoue; Nariman Balenga
Journal:  Ann N Y Acad Sci       Date:  2019-09-09       Impact factor: 5.691

Review 5.  Emerging roles of striatal dopamine D2 receptors in motivated behaviour: Implications for psychiatric disorders.

Authors:  Pedro R Olivetti; Peter D Balsam; Eleanor H Simpson; Christoph Kellendonk
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-06-28       Impact factor: 4.080

6.  Targeting G protein-coupled receptor kinases (GRKs) to G protein-coupled receptors.

Authors:  Sarah M Sulon; Jeffrey L Benovic
Journal:  Curr Opin Endocr Metab Res       Date:  2020-09-18

7.  The Beta-Arrestin-Biased Dopamine D2 Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation.

Authors:  Richard Ågren; Peter Århem; Johanna Nilsson; Kristoffer Sahlholm
Journal:  Int J Neuropsychopharmacol       Date:  2018-12-01       Impact factor: 5.176

Review 8.  GPCR Signaling Regulation: The Role of GRKs and Arrestins.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

9.  GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis.

Authors:  Anup S Pathania; Xiuhai Ren; Min Y Mahdi; Gregory M Shackleford; Anat Erdreich-Epstein
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.996

10.  Noncanonical scaffolding of Gαi and β-arrestin by G protein-coupled receptors.

Authors:  Jeffrey S Smith; Thomas F Pack; Asuka Inoue; Claudia Lee; Kevin Zheng; Issac Choi; Dylan S Eiger; Anmol Warman; Xinyu Xiong; Zhiyuan Ma; Gayathri Viswanathan; Ian M Levitan; Lauren K Rochelle; Dean P Staus; Joshua C Snyder; Alem W Kahsai; Marc G Caron; Sudarshan Rajagopal
Journal:  Science       Date:  2021-01-21       Impact factor: 63.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.